Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: NVAX

Novavax, Inc.

Healthcare | Biotechnology

No licensed closing price on file for NVAX. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$-1.35

Novavax, Inc. (NASDAQ: NVAX) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 09:35 UTC.

What Novavax, Inc. does

Novavax is a vaccine company that develops vaccines using its proprietary Matrix-M adjuvant and recombinant protein-based nanoparticle technology platform. The company's Matrix-M adjuvant is designed to strengthen immune responses when added to vaccines and has been incorporated into its authorized COVID-19 vaccine and a malaria vaccine developed with the University of Oxford.

Summarized from Novavax, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation
EPS (TTM)$-1.35

Revenue, margins & earnings

FY2021: net loss $1.74B on revenue $1.15B$1.15BFY2021FY2022: net loss $658M on revenue $1.98B$1.98BFY2022FY2023: net loss $545M on revenue $984M$984MFY2023FY2024: net loss $187M on revenue $682M$682MFY2024FY2025 Net income: $440MFY2025 Operating costs: $671M$1.12BFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity
Source: SEC EDGAR · Filed 2026-06-23
Most recent filed transactions — June 2026:
  • 2026-06-23DirectorRestricted Stock UnitsAward14,180—
  • 2026-06-23DirectorOption exercise18,880—
  • 2026-06-23DirectorStock Option (Right to Buy)Award21,270—
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Novavax, Inc. do?

Novavax is a vaccine company that develops vaccines using its proprietary Matrix-M adjuvant and recombinant protein-based nanoparticle technology platform.

When did NVAX last file with the SEC?

Novavax, Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-23. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 09:35 UTC. This page is also available as JSON at /api/data?ticker=NVAX and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for NVAX and 5,000+ tickers.

Create a free account — keep NVAX
For your agent
GET /api/data?ticker=NVAX

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt